Présentation de l'entreprise
Tevogen Bio Holdings Inc., identified by the ticker TVGN, operates as a clinical-stage specialty immunotherapy company dedicated to developing off-the-shelf, precision T cell therapies designed for the treatment of infectious diseases, cancers, and various other disorders. The entity functions within the broader Healthcare sector, specifically navigating the complex and high-risk Biotechnology industry, which is characterized by significant capital expenditure and prolonged research and development cycles before products reach commercialization. The company's current scale is defined by a market capitalization of $24.19M, an annual revenue figure that is currently unavailable for calculation, and an organizational structure comprising 18 employees. These metrics indicate that Tevogen Bio is a micro-cap enterprise with a very limited workforce, suggesting a highly concentrated management team focused on early-stage asset development rather than commercial-scale manufacturing or sales operations. The absence of reported revenue further contextualizes the company's position as an entity still in the clinical validation phase, where value is derived primarily from intellectual property and pipeline potential rather than immediate cash flow generation.
Santé financière
The financial performance of Tevogen Bio Holdings Inc. for the trailing twelve months reflects the typical economics of a pre-revenue biotechnology firm, with no reported revenue figures available and a net income of $-26,825,432. The EBITDA for the same period stands at $-25,949,942, revealing a substantial gap between revenue and net income driven by heavy operational expenses, though the lack of revenue data prevents a precise analysis of cost-to-revenue ratios. Free cash flow is reported at $-1,774,858, indicating that the company is burning cash to fund its clinical trials and operational needs, thereby limiting its immediate financial flexibility for external expansion or acquisitions. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that is mathematically consistent with the absence of revenue but also highlights that the company has not yet achieved profitability or positive contribution margins from commercial sales. In terms of balance sheet composition, the company holds $552,372 in cash against total debt obligations of $7.50M, resulting in a negative net cash position that necessitates continuous fundraising to sustain operations. The debt-to-equity ratio is listed as N/A due to the financial structure, while the current ratio of 0.22 indicates a significant liquidity shortfall where current liabilities substantially exceed current assets. Return on Equity is N/A, whereas the Return on Assets metric is reported at -416.5%, a negative figure that underscores the company's aggressive expenditure relative to its asset base and confirms that management is currently unable to generate returns on the capital invested.
Évaluation de la valorisation
Valuation metrics for Tevogen Bio Holdings Inc. present a mixed picture typical of speculative biotech assets, with both the trailing P/E ratio and forward P/E ratio listed as N/A due to the lack of positive earnings data. The price-to-book ratio is calculated at -2.74, a negative multiple that technically indicates the market values the company below its book value or reflects the accounting treatment of its intangible assets and negative net equity. The price-to-sales ratio and EV/EBITDA are also reported as N/A and -1.54 respectively, suggesting that traditional revenue-based valuation models are not applicable while the negative EV/EBITDA highlights the company's net loss position relative to its enterprise value. The stock's price range over the last year has fluctuated between a 52-week low of $4.13 and a 52-week high of $75.50, meaning the current trading price sits significantly below the previous year's peak, reflecting the high volatility and uncertainty inherent in the clinical-stage biotechnology sector. The beta value is recorded at -0.30, an unusual negative coefficient that implies the stock's price movements tend to move inversely to the broader market or are driven by idiosyncratic factors rather than general market sentiment.
Growth & Income
Growth metrics for the company are currently undefined, as revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which precludes any comparison between the pace of earnings expansion versus revenue expansion. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all available cash to fund its research and development pipeline rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage immunotherapy companies that must prioritize capital allocation toward advancing their pipeline assets through clinical trials rather than providing income streams. Consequently, the overall growth and income profile of Tevogen Bio Holdings Inc. is characterized by an exclusive focus on capital appreciation potential through future product approvals, with no current contribution to shareholder income or established historical growth rates to analyze.